• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease.

作者信息

Angelkort B, Kiesewetter H

出版信息

Scand J Clin Lab Invest Suppl. 1981;156:185-8. doi: 10.3109/00365518109097457.

DOI:10.3109/00365518109097457
PMID:6948383
Abstract

The fluidity of blood is a significant factor for the functioning and maintenance of the microcirculation. In chronic arterial occlusive disease (COAD) the fluidity of erythrocytes is markedly reduced assessed by flow rates through a 5-micrometer pore filter system in simulation of microcirculatory conditions. Risk factors such as heavy smoking, hyperfibrinogenaemia and hypertriglyceridaemia as well as hyperfibrinogenaemia result in flow rates similar to those in patients with COAD. Isolated coagulation phenomena typical for hypercoagulability in such patients produce significantly reduced flow rates and indicate the necessity for therapeutic elimination of risk factors as well as improvement of erythrocyte fluidity, reduction of platelet hyper-reagibility and removal of hypercoagulability. Pentoxifylline effects increases in erythrocyte fluidity, decreases platelet hyper-reactivity and plasmatic hypercoagulability, and improves the fibrinolytic capacity of blood in patients with COAD.

摘要

相似文献

1
Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease.
Scand J Clin Lab Invest Suppl. 1981;156:185-8. doi: 10.3109/00365518109097457.
2
Blood fluidity and coagulation phenomena in chronic arterial occlusive disease.慢性动脉闭塞性疾病中的血液流动性和凝血现象。
J Int Med Res. 1980;8(3):242-6. doi: 10.1177/030006058000800310.
3
Significance of antithrombotic effect in drug therapy of the chronic arterial occlusive disease.抗血栓形成作用在慢性动脉闭塞性疾病药物治疗中的意义。
Ric Clin Lab. 1981;11 Suppl 1:215-21.
4
Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.
Angiology. 1984 Jul;35(7):459-66. doi: 10.1177/000331978403500709.
5
[Thrombocytic function, plasmatic blood coagulation and fibrinolysis in chronic arterial occlusive disease. Study with pentoxifilline].[慢性动脉闭塞性疾病中的血小板功能、血浆凝血及纤维蛋白溶解。己酮可可碱研究]
Med Welt. 1979 Aug 24;30(34):1239-43.
6
Pentoxifylline -- a biomedical profile.
J Med. 1979;10(5):307-29.
7
Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline.
Pharmatherapeutica. 1980;2(6):372-9.
8
Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease.
Curr Med Res Opin. 1979;6(4):255-8. doi: 10.1185/03007997909109432.
9
The effect of pentoxifylline on the flow properties of human blood.
Curr Med Res Opin. 1978;5(8):608-13. doi: 10.1185/03007997809110195.
10
Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.
Angiology. 1985 Sep;36(9):628-37. doi: 10.1177/000331978503600907.

引用本文的文献

1
[Predictor function of hemorheologic parameters with reference to the incidence of manifest circulatory disorders: Concept of the Aachen study].
Klin Wochenschr. 1986 Jul 15;64(14):653-62. doi: 10.1007/BF01726918.
2
24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas.通过人工内分泌胰腺评估口服己酮可可碱后 I 型和 II 型糖尿病患者的 24 小时血糖模式。
Acta Diabetol Lat. 1987 Jul-Sep;24(3):181-92. doi: 10.1007/BF02732036.
3
The effect of denbufylline on the viscosity of rat whole blood and on the deformability (filterability) of rat blood cell suspensions.
Naunyn Schmiedebergs Arch Pharmacol. 1987 Apr;335(4):445-8. doi: 10.1007/BF00165561.
4
Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease.IIb期外周动脉闭塞性疾病的保守药物治疗与步行锻炼
Klin Wochenschr. 1986 Oct 15;64(20):1061-9. doi: 10.1007/BF01757212.
5
Oxpentifylline treatment of venous ulcers of the leg.己酮可可碱治疗腿部静脉溃疡
BMJ. 1990 Apr 14;300(6730):972-5. doi: 10.1136/bmj.300.6730.972.
6
Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.己酮可可碱作为外周血管疾病中自由基生成抑制剂的应用。一项双盲安慰剂对照研究的结果。
Eur J Clin Pharmacol. 1991;41(6):511-5. doi: 10.1007/BF00314976.